|
I'm not sure http://egotastic.in.net egotastic all stars Rigel Pharmaceuticals Inc. (RIGL) said an investigational drug didn't meet primary endpoints in a Phase II stage study of patients with discoid lupus erythematosus and it won't pursue further studies of the treatment for that indication.
,
Author: - Kirjoittanut: Anonymous, 05/22/2019, |